This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Adrenogenital Disorder, Unspecified / CAH NOS / AGS NOS부신생식기증후군 NOS (상세불명)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E25.9 (Adrenogenital disorder, unspecified) | Special Copayment Reduction: V115 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsAdrenogenital syndrome NOS, adrenogenital syndrome unspecified, congenital adrenal hyperplasia NOS (unspecified), adrenogenital disorder NOS, Adrenogenital syndrome NOS, Congenital adrenal hyperplasia NOS, Adrenogenital disorder unspecified
C. Adult onsetPossibility of first presentation in adulthood: yes (mild subtypes) — E25.9 is a residual diagnostic code covering adrenogenital disorders in which no specific enzyme deficiency has been confirmed; nonclassic adrenal hyperplasia or mild steroid metabolism abnormalities may be first detected in adulthood; on final confirmation, the code transitions to a specific code such as E25.0.
1. HistoryMid-19th century: first description of the association between adrenal and genital abnormalities → established in the history of ICD classification as a residual code including cases with unidentified CAH subtypes → trend toward transition to detailed codes with advances in molecular diagnosis.
2. CausesAdrenal steroidogenic enzyme deficiencies (other than 21-OH), adrenal steroid receptor abnormalities, unclassified adrenal steroid metabolism abnormalities; includes cases of unknown cause or without genetic testing.
3. GeneticsMostly presumed autosomal recessive; gene unidentified or possibly multiple genes; various genes may be involved, including 11β-OH deficiency (CYP11B1), 3β-HSD2 (HSD3B2), 17α-OH (CYP17A1), StAR, and CYP11A1.
4. General epidemiologyConsiderable numbers if nonclassic and unclassified adrenogenital disorders are included; use of the E25.9 code is declining with the introduction of screening and expansion of molecular diagnosis; actual frequency of use in Korea is limited.
5. PathophysiologyImpairment at various steps of the adrenal steroid synthesis pathway → variable depending on the degree of cortisol and aldosterone deficiency → androgen excess or sex hormone imbalance → ACTH overstimulation → adrenal hyperplasia.
6. SymptomsAbnormal external genital development (virilization in girls or genital abnormalities in boys), precocious puberty or delayed development, hirsutism, acne, and irregular menses (mild subtypes), hypertension (11β-OH deficiency subtype), hyponatremia and hyperkalemia (salt-wasting subtype).
7. SignsAdrenal hyperplasia (imaging), abnormal pattern of serum steroid metabolites, elevated androgens, elevated ACTH; depending on the subtype, variable elevation of 17-OHP, 11-deoxycortisol, DHEA-S, etc.
8. ScreeningNeonatal 17-OHP screening (mainly targets E25.0); when the E25.9 category is suspected, comprehensive steroid profiling (GC-MS/LC-MS/MS), ACTH stimulation test, adrenal imaging, and gene panel analysis are recommended.
9. DiagnosisComprehensive adrenal steroid profile (serum and urine); ACTH stimulation test; adrenal CT/MRI; multigene NGS panel (including all CAH-related enzyme genes); evaluation for differences of sex development (DSD panel).
10. TreatmentGlucocorticoid and mineralocorticoid replacement therapy according to the confirmed subtype; empirical hydrocortisone if the cause is unknown; stress-dose protocol; surgical correction of external genitalia; long-term follow-up.
11. PrognosisVariable depending on the confirmed enzyme deficiency subtype and severity; generally good with appropriate treatment; adrenal crisis and androgen excess complications are the main causes of morbidity; early diagnosis is a decisive factor in prognosis.
12. PreventionNewborn screening; genetic counseling; testing of family carriers; education on stress preparedness; follow-up testing system; clear subtype classification through molecular diagnosis to confirm a higher-level code such as E25.0.
13. ReferencesClaahsen-van der Grinten HL et al. Congenital adrenal hyperplasia — current insights … and 9 other papers

1. History

Adrenogenital syndrome NOS (E25.9) in the ICD-10 classification system denotes abnormal genital development or function due to abnormal adrenal steroid metabolism, and is a residual diagnostic code (residual category) used when a specific enzyme deficiency has not been confirmed or is not specified. To understand the historical background of this code, it is necessary to look at the classification history of adrenogenital disorders as a whole.

In the mid-19th century, Luigi de Crecchio (1865) and John Phillips (1886) described clinical cases in which adrenal abnormalities coexisted with abnormal external genital development. At the time, such conditions were collectively called "adrenal-genital associated syndrome" or simply "hermaphroditism." In the early 20th century, clinical observations accumulated that adrenal tumors or adrenal enlargement were associated with virilization, and in the 1920s–1930s the term "adrenogenital syndrome" came into wide use.

In the 1950s, Wilkins, Bongiovanni, and others elucidated the pathophysiology of cortisol deficiency and androgen excess, and by the 1960s, as major enzyme-deficiency subtypes such as 21-hydroxylase, 11β-hydroxylase, and 3β-HSD were described in turn, the overarching concept of "congenital adrenal hyperplasia (CAH)" was established. However, during this period, owing to the limitations of biochemical testing, there were many cases in which the specific enzyme could not be identified, and these unclassified cases were recorded under the names "adrenogenital syndrome NOS" or "congenital adrenal hyperplasia NOS."

In the 1970s–1980s, as steroid hormone quantification using radioimmunoassay (RIA) developed, the ability to distinguish specific enzyme deficiencies biochemically improved greatly. With the cloning of the CYP21A2 gene in 1984 and subsequent identification of genes such as CYP11B1, HSD3B2, and CYP17A1, molecular diagnosis became possible. Accordingly, cases previously classified as "NOS" gradually transitioned to specific codes (E25.0, E25.8, etc.).

In the current International Classification of Diseases ICD-10, E25.9 is "Adrenogenital disorder, unspecified" and functions as a code used when an adrenogenital disorder is clinically clearly present but the specific enzyme deficiency or cause has not been identified, or provisionally during the diagnostic process. The conceptual definition of this code is expected to become clearer in the transition to ICD-11. In Korea, it is linked to the rare disease Special Copayment Reduction code V115, so the Special Copayment Reduction benefit can be applied even when the E25.9 code is assigned. However, once a final diagnosis is made, the principle is to update to E25.0 or a more specific code.

With the continuing development of molecular diagnostic technology, cases that previously remained unclassified are being identified through next-generation sequencing (NGS) as new gene variants or abnormalities in genes not previously associated with CAH. For example, familial glucocorticoid deficiency due to NNT (nicotinamide nucleotide transhydrogenase) gene variants, and MC2R (ACTH receptor), MRAP, and STAR variants have recently been described as new adrenal steroidogenesis disorders, and patients in the E25.9 category are continually being re-evaluated.


2. Causes

Adrenogenital syndrome NOS (E25.9) is, by definition, a code covering adrenogenital disorders whose specific cause has not been identified or is not specified. The potential causes of clinical cases that can be classified under this code are diverse.

Adrenal steroidogenic enzyme deficiencies (other than 21-hydroxylase)

11β-hydroxylase (CYP11B1) deficiency, the second most common cause of congenital adrenal hyperplasia, accounts for approximately 5–8% of all CAH and is characterized by hypertension due to accumulation of 11-deoxycortisol and 11-deoxycorticosterone (DOC). Because this subtype is not detected by 17-OHP screening systems, it may initially be classified as an adrenogenital abnormality of unknown cause. 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) deficiency shows a characteristic pattern of markedly elevated DHEA and DHEA-S with only mild 17-OHP elevation, and mild genital abnormalities can also occur in boys. 17α-hydroxylase/17,20-lyase (CYP17A1) deficiency is characterized by sex hormone deficiency and hypertension and is a rare subtype presenting as 46,XY DSD with a female phenotype or as abnormal pubertal development in girls.

Abnormalities of the early steroid synthesis pathway

Cholesterol side-chain cleavage enzyme (CYP11A1) deficiency and lipoid adrenal hyperplasia (StAR deficiency) are disorders of the very first step of steroid synthesis, resulting in severe adrenal insufficiency in which no steroid hormones can be produced and a completely female external genital phenotype in 46,XY fetuses. They are very rare and present with acute adrenal insufficiency in the neonatal period. P450 oxidoreductase (POR) deficiency is a deficiency of POR, the electron-donating enzyme for multiple cytochrome P450 enzymes (CYP21A2, CYP17A1, CYP19A1, etc.), causing combined steroid synthesis abnormalities, and is sometimes accompanied by skeletal abnormalities (Antley-Bixler syndrome).

Abnormalities of adrenal steroid regulation

Familial glucocorticoid deficiency (FGD) due to ACTH receptor (MC2R) mutations or ACTH receptor accessory protein (MRAP) deficiency causes cortisol deficiency and androgen excess (due to excessive ACTH secretion) and can present with an adrenogenital phenotype. Adrenal insufficiency due to excess oxidative stress caused by NNT gene variants is also a newly described cause.

Cases of unknown cause or under diagnostic workup

E25.9 is actually used frequently in situations where an adrenogenital abnormality is clinically clear but ① genetic testing has not been performed, ② test results are pending, or ③ no causative variant was identified on a standard gene panel. In these patients, a new genetic cause may be identified through additional molecular diagnosis (whole-exome or whole-genome sequencing).


3. Genetics

Most disorders that may fall in the adrenogenital syndrome NOS (E25.9) category follow an autosomal recessive mode of inheritance, but cases in which the specific gene and variant have not been identified are also included. The main potentially related genes and their genetic characteristics are summarized below.

CYP11B1 (11β-hydroxylase deficiency, OMIM #202010)

Located on the long arm of chromosome 8 (8q24.3). Autosomal recessive. More than about 100 pathogenic variants reported. High incidence in Middle Eastern and Moroccan Jewish populations, with a founder effect observed. Elevated 11-deoxycortisol (substance S, compound S), rather than 17-OHP, is the diagnostic marker. Because neonatal 17-OHP screening is negative, there is a risk of delayed diagnosis.

HSD3B2 (3β-HSD2 deficiency, OMIM #201810)

Located on the short arm of chromosome 1 (1p13.1). Autosomal recessive. Characterized by genital abnormalities such as hypospadias and cryptorchidism in boys and mild clitoromegaly in girls. Marked elevation of DHEA and DHEA-S is the key biochemical finding. The severe form is accompanied by salt-wasting crisis in the neonatal period.

CYP17A1 (17α-hydroxylase deficiency, OMIM #202110)

Located on the long arm of chromosome 10 (10q24.32). Autosomal recessive. Global blockade of sex hormone (cortisol, gonadal steroid) production; hypertension and hypokalemia due to DOC accumulation. Completely female phenotype in 46,XY patients and amenorrhea in 46,XX. Relatively high frequency reported in Asian (Southeast Asia, China, Taiwan, Brazil) populations.

StAR (lipoid adrenal hyperplasia, OMIM #201710)

Located on the short arm of chromosome 8 (8p11.23). Autosomal recessive. Steroidogenic acute regulatory protein (StAR) deficiency blocks the earliest step of all steroid synthesis. Characterized by extreme adrenal insufficiency in the neonatal period and completely female external genitalia in 46,XY individuals. Highly lethal, with a high risk of death without early detection.

POR (P450 oxidoreductase deficiency, OMIM #613571)

Located on the long arm of chromosome 7 (7q11.23). Autosomal recessive. Simultaneous dysfunction of multiple cytochrome P450 enzymes → incomplete virilization (boys) + incomplete feminization (girls) + maternal virilization during pregnancy + possible skeletal abnormalities. First described by Flück et al. in 2004. Distinctive pattern on urinary steroid profile.

Because the various genes above are involved, when E25.9 is diagnosed it is recommended to select the relevant genes through detailed biochemical evaluation and, where possible, to perform a multigene NGS panel (including all genes related to adrenal steroid synthesis) to establish the final genetic diagnosis.


4. General epidemiology

Because adrenogenital syndrome NOS (E25.9) is a residual classification code rather than a specific disease, independent epidemiological data are limited. In actual clinical practice, this code is used provisionally during the diagnostic workup of adrenogenital disorders or when a specific cause has not been identified, so in the long run it is often converted to E25.0 (21-hydroxylase deficiency) or another specific code.

The worldwide incidence of classic congenital adrenal hyperplasia as a whole (including E25.0) is estimated at approximately 1:10,000–15,000. Of these, 21-hydroxylase deficiency accounts for 95%, 11β-hydroxylase deficiency for approximately 5–8%, and the remaining enzyme deficiencies combined for less than 1%. The actual frequency of unclassified or unspecified adrenogenital disorders corresponding to E25.9 is unclear, but the frequency of use of this code tends to decline as molecular diagnostic systems develop.

In Korea, with the introduction of newborn screening in 2006 and improved access to NGS-based molecular diagnosis since the 2010s, the proportion of E25.9 code use has been steadily declining. In Health Insurance Review & Assessment Service (HIRA) data, the number of patients billed under the E25.9 code is small, which is interpreted as mostly corresponding to a provisional stage before diagnostic confirmation. For 11β-hydroxylase deficiency, specific data on incidence in Korea are limited, and it is estimated to be relatively lower in Asian populations than in Middle Eastern and North African populations. CYP17A1 deficiency tends to be reported at a relatively higher frequency in East Asian populations, including Korea, than in Western populations, which should be kept in mind in differential diagnosis.

Regarding sex distribution, disorders in the E25.9 category are genetically sex-independent, but clinical presentation differs by sex (virilization in girls vs. genital abnormalities in boys vs. hormonal abnormalities in adult women), and there are differences in the trigger and timing of diagnosis. In particular, 46,XY patients with CYP17A1 deficiency are often raised as female, which can make diagnosis more complicated.


5. Pathophysiology

Although no specific enzyme has been identified in adrenogenital syndrome NOS, its fundamental pathophysiological framework is the same as in other CAH subtypes, including E25.0 (21-hydroxylase deficiency): the following cascade caused by impairment at a specific step of the adrenal steroid synthesis pathway.

The steroid synthesis pathway, starting from cholesterol, begins with cholesterol transport into the mitochondria by the StAR protein and proceeds in the order CYP11A1 (cholesterol side-chain cleavage), 3β-HSD2, CYP17A1, CYP21A2, CYP11B1/CYP11B2, ultimately producing cortisol and aldosterone. If enzyme activity is lost or reduced at any step of this pathway, the substrate before that step accumulates and the product after that step decreases.

Whatever the step of enzyme deficiency, when cortisol production decreases, negative feedback to the hypothalamus-pituitary weakens and ACTH is oversecreted. ACTH continuously stimulates the adrenal cortex, causing bilateral adrenocortical hyperplasia. At the same time, as unblocked pathways are overactivated by ACTH overstimulation, androgen (DHEA, androstenedione) production increases, or the substrate accumulated before the blocked step is diverted into the androgen synthesis pathway.

The clinical phenotype varies with the step of enzyme deficiency. In 11β-hydroxylase deficiency, 11-deoxycorticosterone (DOC) has potent mineralocorticoid activity, so hypertension and hypokalemia occur. In 3β-HSD2 deficiency, DHEA and DHEA-S increase markedly, but conversion to potent androgens (testosterone) is limited, so boys may paradoxically show incomplete virilization (hypospadias). In CYP17A1 deficiency, neither sex hormone precursors nor cortisol are synthesized, resulting in sex hormone deficiency from both the gonads and the adrenals.

The mechanism by which virilization of the female external genitalia occurs as a result of fetal androgen excess is the same as in E25.0, but the type (testosterone vs. DHEA) and degree of excess androgen differ by subtype. In male fetuses, incomplete virilization paradoxically occurs in subtypes with androgen deficiency (complete blockade of steroid synthesis, CYP17A1 deficiency, StAR deficiency). This diversity explains the clinical heterogeneity of the E25.9 category.


6. Symptoms

The symptoms of adrenogenital syndrome in the E25.9 category vary depending on the underlying subtype, but adrenal steroid abnormalities and abnormal sexual development predominate in common. The main symptom groups that raise clinical suspicion are as follows.

Symptoms in the neonatal period to infancy

Symptoms in childhood to adolescence

Symptoms in adulthood (nonclassic or mild subtypes)

Risk of adrenal crisis common to all subtypes: inability to rapidly increase cortisol in stressful situations → hypotension, hypoglycemia, hyponatremia, nausea/vomiting, decreased consciousness → risk of death if untreated.


7. Signs

The objective signs of E25.9 adrenogenital syndrome NOS differ depending on the related subtype, but the main findings that can be identified clinically are described below.

Physical examination findings

Biochemical signs (by subtype)

Imaging findings

Bilateral adrenal enlargement (diffuse or nodular) is commonly observed on abdominal CT or MRI. In StAR deficiency, massive adrenals with excessive lipid accumulation are characteristic. Bone X-rays show advanced bone age, and in children, bone age assessment by wrist X-ray is used for treatment monitoring.


8. Screening

Systematic screening for adrenogenital syndrome in the E25.9 category is not as standardized as for E25.0 (21-hydroxylase deficiency). However, when clinically suspected, a comprehensive testing approach is needed.

Limitations of newborn screening

Current newborn screening in Korea measures 17-OHP and therefore mainly detects 21-hydroxylase deficiency (E25.0). Subtypes that may fall in the E25.9 category, such as 11β-hydroxylase deficiency, 3β-HSD2 deficiency, CYP17A1 deficiency, and StAR deficiency, may be missed by 17-OHP screening. However, in 3β-HSD2 deficiency, 17-OHP is sometimes mildly elevated and picked up as a false positive in screening, though specificity is low.

Screening based on clinically suspicious findings

Urinary steroid profile (GC-MS/LC-MS/MS)

Quantitative analysis of steroid metabolites in 24-hour or random urine is the most comprehensive test for identifying which enzyme step is blocked. It can be performed at specialized laboratories, analyzing urine collected at baseline or after ACTH stimulation. When an abnormal pattern is identified, the corresponding gene is tested first.

Multigene NGS panel

When it is difficult to confirm a specific subtype by clinical and biochemical evaluation, a multigene NGS panel including genes related to adrenal steroid synthesis (CYP21A2, CYP11B1, CYP11B2, HSD3B2, CYP17A1, CYP11A1, StAR, POR, MC2R, MRAP, etc.) allows multiple subtypes to be evaluated simultaneously in a single test.


9. Diagnosis

Diagnosis of E25.9 adrenogenital syndrome NOS requires a comprehensive approach including the following steps.

Step 1: Initial clinical and biochemical evaluation

Step 2: ACTH stimulation test

Measure 17-OHP, 11-deoxycortisol, DHEA, androstenedione, and cortisol before and after (0, 30, 60 minutes) administration of cosyntropin (synthetic ACTH, 250 µg IV). Analyze subtype-specific response patterns using a new nomogram. Low-dose ACTH stimulation (1 µg) can also be used in children.

Step 3: Urinary steroid profile

Urinary steroid metabolite profiling using GC-MS or LC-MS/MS. Comprehensive measurement of the products and precursors of each step of the adrenal steroid synthesis pathway. Identification of subtype-specific patterns.

Step 4: Molecular genetic testing

Priority testing of target genes according to the biochemical pattern, or a multigene NGS panel. CYP21A2 analysis (including MLPA + long-range PCR), CYP11B1, HSD3B2, CYP17A1, StAR, CYP11A1, POR, etc. If the panel is negative, consider whole-exome or genome sequencing.

Differential diagnosis


10. Treatment

Treatment of E25.9 adrenogenital syndrome NOS is started empirically until the diagnosis is confirmed, and is switched to subtype-appropriate treatment once the subtype is identified. In general, glucocorticoid replacement is the common treatment principle for all subtypes.

Emergency treatment (salt-wasting crisis or adrenal crisis)

Long-term hormone replacement therapy

After the causative subtype is identified, dose and formulation are adjusted appropriately. The basic principles are the same as for E25.0.

Hypertension management (11β-hydroxylase deficiency, CYP17A1 deficiency)

If hypertension due to DOC excess persists even after adequate glucocorticoid replacement, consider adding a mineralocorticoid receptor antagonist (spironolactone, eplerenone) or a calcium channel blocker.

Surgical treatment

In girls with abnormal external genitalia, whether, when, and how to perform feminizing genitoplasty is decided in consultation with a multidisciplinary DSD team (pediatric endocrinology, pediatric urology, pediatric surgery, child psychology, clinical genetics, nursing team). Ethical considerations (the future adult's autonomy, gender identity, etc.) are thoroughly reviewed.


11. Prognosis

The prognosis of E25.9 adrenogenital syndrome NOS varies greatly depending on the underlying subtype, severity, timing of diagnosis, and adequacy of treatment. In general, the prognosis is relatively good when appropriate hormone replacement therapy and continuous follow-up are provided.

Survival and acute complications

In severe subtypes (StAR deficiency, CYP11A1 deficiency), extreme adrenal insufficiency in the neonatal period carries a high risk of death if treatment is delayed. In other subtypes as well, salt-wasting crisis or adrenal crisis is life-threatening without immediate treatment. In settings with systematic newborn screening, such as Korea, early detection and treatment have greatly reduced the occurrence of these acute complications.

Growth prognosis

Similar to 21-hydroxylase deficiency (E25.0), in other enzyme-deficiency subtypes, final height may also be reduced due to accelerated bone maturation from androgen excess before treatment. This can be minimized with early diagnosis and treatment. In 11β-hydroxylase deficiency, cardiovascular complications related to hypertension caused by DOC excess affect long-term prognosis.

Reproductive prognosis

In women, ovulation and pregnancy are possible once androgen excess is treated, but fertility is reduced when the untreated period was long or androgen excess was severe. In 46,XX patients with CYP17A1 deficiency, pubertal development is induced with appropriate estrogen supplementation, but reproductive dysfunction persists due to endogenous sex hormone deficiency. In 46,XY patients with CYP17A1 deficiency, there is a risk of malignant transformation of the internal gonads (testes), so prophylactic gonadectomy is considered.

Psychosocial prognosis

Abnormal external genitalia, sex assignment issues, pubertal abnormalities, and the burden of chronic medication affect psychosocial adjustment. Long-term psychosocial support and regular mental health evaluation should be included in comprehensive management.


12. Prevention

Prevention strategies for E25.9 adrenogenital syndrome NOS share much with those for E25.0, but additional considerations are needed due to subtype uncertainty.

Primary prevention: genetic counseling and prenatal diagnosis

When there is an affected child or the subtype gene has been identified, genetic counseling is used to discuss the recurrence risk in the next pregnancy (25%) and prenatal diagnostic options (CVS, amniocentesis, PGT-M). Even when the subtype is unclear, prenatal genetic testing using a comprehensive adrenal steroidogenic enzyme gene panel is possible.

Secondary prevention: strengthening early detection systems

Recognizing the limitation that current newborn screening (17-OHP) focuses on 21-hydroxylase deficiency, comprehensive steroid evaluation should be performed immediately in neonates found to have abnormal external genitalia, even if standard screening is negative. Some countries are attempting to include additional markers such as 11-deoxycortisol in newborn screening.

Confirmatory diagnosis through molecular diagnosis

Recognizing that the E25.9 code is a provisional rather than final diagnostic code, updating it as soon as possible to the appropriate specific code (E25.0, E25.8, etc.) through confirmatory molecular genetic diagnosis provides the basis for accurate treatment, prognostic assessment, and genetic counseling.

Stress preparedness education and long-term follow-up

All patients with adrenal steroid synthesis disorders need education on stress-dose protocols, should always carry emergency hydrocortisone, and should carry a medical alert card. Regular endocrine outpatient follow-up (growth, hormone monitoring, bone age, blood pressure, metabolic markers) and, when needed, psychosocial support and reproductive counseling form an integrated management system.


13. References

  1. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia — current insights in pathophysiology, diagnostics, and management. Endocrine Reviews. 2022;43(1):91–159. DOI: 10.1210/endrev/bnab016. PMID: 33961029.

  2. Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best Practice & Research Clinical Endocrinology & Metabolism. 2009;23(2):181–192. DOI: 10.1016/j.beem.2008.10.014. PMID: 19500762.

  3. Esoterix/LabCorp; Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. Current Opinion in Endocrinology, Diabetes and Obesity. 2017;24(3):252–259. DOI: 10.1097/MED.0000000000000334. PMID: 28319476.

  4. Flück CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley–Bixler syndrome. Nature Genetics. 2004;36(3):228–230. DOI: 10.1038/ng1300. PMID: 14758363.

  5. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. 2017;390(10108):2194–2210. DOI: 10.1016/S0140-6736(17)31431-9. PMID: 28576284.

  6. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2016;101(2):364–389. DOI: 10.1210/jc.2015-1710. PMID: 26760044.

  7. Hughes IA, Houk C, Ahmed SF, Lee PA; LWPES/ESPE Consensus Group. Consensus statement on management of intersex disorders. Archives of Disease in Childhood. 2006;91(7):554–563. DOI: 10.1136/adc.2006.098319. PMID: 16624884.

  8. Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinology and Metabolism Clinics of North America. 2001;30(1):101–119. DOI: 10.1016/s0889-8529(08)70022-0. PMID: 11344933.

  9. Kim CJ, Lin L, Huang N, et al. Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. Journal of Clinical Endocrinology & Metabolism. 2008;93(3):696–702. DOI: 10.1210/jc.2007-2329. PMID: 18182449.

  10. Reisch N, Hogler W, Parajes S, et al. A diagnosis not to be missed: nonclassic steroid 11β-hydroxylase deficiency presenting with premature adrenarche and hirsutism. Journal of Clinical Endocrinology & Metabolism. 2013;98(10):E1620–E1625. DOI: 10.1210/jc.2013-1306. PMID: 23986148.